- Report
- April 2023
- 117 Pages
Global
From €4554EUR$4,750USD£3,805GBP
- Report
- January 2024
- 103 Pages
Global
From €3500EUR$3,911USD£3,027GBP
Hydroxyzine imine, known under various brand names, is part of the dibenzodiazepine class of compounds and has been used to treat a variety of mental disorders. It functions primarily as an antihistamine with secondary anticholinergic and sedative effects, making it useful in the management of anxiety and tension associated with psychoneurosis, as well as adjunctive treatment for alcoholism. Hydroxyzine is also employed pre- and post-operatively to help alleviate anxiety, in the management of pruritus due to allergic conditions, and in cases of nausea and vomiting. In the realm of mental disorders drugs, hydroxyzine is considered a viable option for symptomatic relief of anxiety and tension for patients who seek an intermediary treatment phase before long-term management with anxiolytics.
In the hydroxyzine imine market, several pharmaceutical companies are prominent due to their manufacturing and distribution of the drug in various forms. Some well-known companies include Pfizer, which markets hydroxyzine under the brand name Vistaril, and UCB, which sells it as Atarax. Other companies like Teva Pharmaceuticals and Mylan also provide generic versions of hydroxyzine, catering to a wider market seeking cost-effective options for managing anxiety and related conditions. Show Less Read more